We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

World’s First Test Kit Detects Omicron Variant by Combining Gene Dropout and Mutations Specific Detection

By LabMedica International staff writers
Posted on 10 Jan 2022
Print article
Illustration
Illustration

The world’s first test kit that can detect the B.1.1.529 (Omicron) variant by combining S-gene target failure (SGTF) and S-gene mutation amplification (SGMA) promises to cut down procedural delays in genome sequencing to ascertain the latest SARS-CoV-2 variant.

Tata Medical & Diagnostic Centre (Tamil Nadu, India) has developed the first-of-its-kind RT-PCR test kit dubbed OmiSure that can capture both the gene dropout and specific mutation to detect the Omicron variant of COVID-19 on nasal and oral swab samples. The test is compatible with all common Real-Time PCR devices and has been approved by India’s regulatory body, the Indian Council of Medical Research (ICMR). It has been designed to pick up all SARS-CoV-2 variants, but specifically pulls out Omicron. The test takes about 2.5 hours from specimen collection to reporting and can be performed in all RT-PCR labs without the need for any special training.

OmiSure is a real time PCR test and not a home testing kit as it detects viral genetic material and not viral antigen. It is also not a Rapid Antigen Test (RAT) and reportedly requires a certain amount of bio-safety. The single tube, fully multiplexed test comes with two checks in place for Omicron detection and has reported 100% sensitivity and 99.25% specificity for the detection of variants of SARS-CoV-2, including Omicron.

OmiSure can help eliminate the need for genome sequencing to detect Omicron amidst the fresh surge in cases that is exerting pressure on laboratories across the world. The company is also planning to export OmiSure kits and has applied for licensure to the European Union and US Food and Drug Administration (USFDA).

Related Links:
Tata Medical & Diagnostic Centre 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more